Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 4, 2005, Pages 1397-1403

  Simitsopoulou, M ^a,b   Roilides, E ^a,c   Dotis, J ^a   Dalakiouridou, M ^a   Dudkova, F ^a,d   Andreadou, E ^b   Walsh, T J ^c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ALEXANDER TECHNOLOGICAL EDUCATIONAL INSTITUTE OF THESSALONIKI   (Greece)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CHEMOKINE; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MONOCYTE; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY; UPREGULATION;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; CHEMISTRY, PHARMACEUTICAL; CHEMOKINES; CYTOKINES; DEOXYCHOLIC ACID; GENE EXPRESSION REGULATION; HUMANS; LIPOSOMES; MONOCYTES; RNA, MESSENGER;

EID: 16244388915     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.4.1397-1403.2005     Document Type: Article

References (44)

1. Abu-Salah, K. M. 1996. Amphotericin B: an update. Br. J. Biomed. Sci. 53:122-133.
2. Arend, W. P. 2001. Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist. Semin. Arthritis Rheum. 30:1-6.
3. Arend, W. P., and C. J. Guthridge. 2000. Biological role of interleukin 1 receptor antagonist isoforms. Annu. Rheum. Dis. 59(Suppl. 1):i60-i64.
4. Arning, M., K. O. Kliche, A. H. Heer-Sonderhoff, and A. Wehmeier. 1995. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 38:459-465.
5. Arondel, J., M. Singer, A. Matsukawa, A. Zychlinsky, and P. J. Sansonetti. 1999. Increased interleukin-1 (IL-1) and imbalance between IL-1 and IL-1 receptor antagonist during acute inflammation in experimental shigellosis. Infect. Immun. 67:6056-6066.
6. Blau, I. W., and A. A. Fauser. 2000. Review of comparative studies between conventional and liposomal amphotericin B (Ambisome) in neutropenic patients with fever of unknown origin and patients with systemic mycosis. Mycoses 43:325-332.
7. Bowden, R., P. Chandrasekar, M. H. White, X. Li, L. Pietrelli, M. Gurwith, J. A. van Burik, M. Laverdiere, S. Safrin, and J. R. Wingard. 2002. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis. 35:359-366.
8. Cagnoni, P. J. 2002. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J. Antimicrob. Chemother. 49(Suppl. 1):S1-86.
9. Casini-Raggi, V., L. Kam, Y. J. Chong, C. Fiocchi, T. T. Pizarro, and F. Cominelli. 1995. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J. Immunol. 154:2434-2440.
10. Chomczynski, P., and N. Sacchi. 1987, Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
11. Cleary, J. D., D. Weisdorf, and C. V. Fletcher. 1988. Effect of infusion rate on amphotericin B-associated febrile reactions. Drug Intell. Clin. Pharm. 22:769-772.
12. Dayer, J. M. 2002. Evidence for the biological modulation of IL-1 activity: the role of IL-1Ra. Clin. Exp. Rheumatol. 20:S14-S20.
13. Deray, G. 2002. Amphotericin B nephrotoxicity. J. Antimicrob. Chemother. 49(Suppl. 1):37-41.
14. Dinarello, C. A. 2002. The IL-1 family and inflammatory diseases. Clin. Exp. Rheumatol. 20:S1-S13.
15. Dinarello, C. A.1997. Interleukin-1. Cytokine Growth Factor Rev. 8:253-265.
16. Dinarello, C. A. 1992. Interleukin-1 and tumor necrosis factor: effector cytokines in autoimmune diseases. Semin. Immunol. 4:133-145.
17. Dupont, B. 2002. Overview of the lipid formulations of amphotericin B. J. Antimicrob. Chemother. 49(Suppl. 1):31-36.
18. Emery, P., and Y. Seto. 2003. Role of biologies in early arthritis. Clin. Exp. Rheumatol. 21:S191-S194.
19. Goodwin, S. D., J. D. Cleary, C. A. Walawander, J. W. Taylor, and T. H. Grasela, Jr. 1995. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin. Infect. Dis. 20:755-761.
20. Granowitz, E. V., B. D. Clark, E. Vannier, M. V. Callahan, and C. A. Dinarello. 1992. Effect of interleukin-1 (IL-1) blockade on cytokine synthesis. I. IL-1 receptor antagonist inhibits IL-1-induced cytokine synthesis and blocks the binding of IL-1 to its type II receptor on human monocytes. Blood 79:2356-2363.
21. Groll, A. H., J. C. Gea-Banacloche, A. Glasmacher, G. Just-Nuebling, G. Maschmeyer, and T. J. Walsh. 2003. Clinical pharmacology of antifungal compounds. Infect. Dis. Clin. N. Am. 17:159-191, ix.
22. Hann, I. M., and H. G. Prentice. 2001. Lipid-based amphotericin B: a review of the last 10 years of use. Int. J. Antimicrob. Agents 17:161-169.
23. Martino, R. 2004. Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature. Curr. Med. Res. Opin. 20:485-504.
24. Moser, B., M. Wolf, A. Walz, and P. Loetscher. 2004. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 25:75-54.
25. Ostrosky-Zeichner, L., K. A. Marr, J. H. Rex, and S. H. Cohen. 2003. Amphotericin B: time for a new "gold standard." Clin. Infect. Dis. 37:415-425.
26. Rogers, P. D., J. K. Jenkins, S. W. Chapman, K. Ndebele, B. A. Chapman, and J. D. Cleary. 1998. Amphotericin B activation of human genes encoding for cytokines. J. Infect. Dis. 178:1726-1733.
27. Rogers, P. D., R. E. Kramer, S. W. Chapman, and J. D. Cleary. 1999. Amphotericin B-induced interleukin-1beta expression in human monocytic cells is calcium and calmodulin dependent. J. Infect. Dis. 180:1259-1266.
28. Rogers, P. D., M. M. Pearson, J. D. Cleary, D. C. Sullivan, and S. W. Chapman. 2002. Differential expression of genes encoding immunomodulatory proteins in response to amphotericin B in human mononuclear cells identified by cDNA microarray analysis. J. Antimicrob. Chemother. 50:811-817.
29. Rogers, P. D., J. K. Stiles, S. W. Chapman, and J. D. Cleary. 2000. Amphotericin B induces expression of genes encoding chemokines and cell adhesion molecules in the human monocytic cell line THP-1. J. Infect. Dis. 182:1280-1283.
30. Roilides, E., I. Kadiltsoglou, A. Dimitriadou, M. Hatzistilianou, A. Manitsa, J. Karpouzas, P. A. Pizzo, and T. J. Walsh. 1997. Interleukin-4 suppresses antifungal activity of human mononuclear phagocytes against Candida albicans in association with decreased uptake of blastoconidia. FEMS Immunol. Med. Microbiol. 19:169-180.
31. Roilides, E., C. G. Lamaignere, and E. Farmaki. 2002. Cytokines in immunodeficient patients with invasive fungal infections: an emerging therapy. Int. J. Infect. Dis. 6:154-163,
32. Rollins, B. J. 1996, Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Mol. Med. Today 2:198-204.
33. Sau, K., S. S. Mambula, E. Latz, P. Henneke, D. T. Golenbock, and S. M. Levitz. 2003. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependem mechanism. J. Biol. Chem. 278:37561-37568,
34. Schindler, R., B. D. Clark, and C. A. Dinarello. 1990. Dissociation between interleukin-1 beta mRNA and protein synthesis in human peripheral blood mononuclear cells. J. Biol. Chem. 265:10232-10237.
35. Schottelius, A. J., L. L. Moldawer, C. A. Dinarello, K. Asadullah, W. Sterry, and C. K. Edwards III. 2004. Biology of tumor necrosis factor-alpha-implications for psoriasis. Exp. Dermatol. 13:193-222.
36. Shadkchan, Y., Y. Keisari, and E. Segal. 2004. Cytokines in mice treated with amphotericin B-intralipid. Med. Mycol. 42:123-128.
37. Shimauchi, H., S. Takayama, T. Imai-Tanaka, and H. Okada. 1998. Balance of interleukin-1 beta and interleukin-1 receptor antagonist in human periapical lesions. J. Endod. 24:116-119.
38. Tiphine, M., V. Letscher-Bru, and R. Herbrecht. 1999. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transplant. Infect. Dis. 1:273-283.
39. Turtinen, L. W., D. N. Prall, L. A. Bremer, R. E. Nauss, and S. C. Hartsei. 2004. Antibody array-generated profiles of cytokine release from THP-1 leukemic monocytes exposed to different amphotericin B formulations. Antimicrob. Agents Chemother. 48:396-403.
40. Vonk, A. G., M. G. Netea, N. E. Denecker, I. C. Verschueren, J. W. van der Meer, and B. J. Kullberg. 1998. Modulation of the pro- and anti-inflammatory cytokine balance by amphotericin B. J. Antimicrob. Chemother. 42:469-474.
41. Walsh, T. J., R. W. Finberg, C. Arndt, J. Hiemenz, C. Schwartz, D. Bodensteiner, P. Pappas, N. Seibel, R. N. Greenberg, S. Dummer, M. Schuster, J. S. Holcenberg et al. 1999. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 340:764-771.
42. Walsh, T. J., J. L. Goodman, P. Pappas, I. Bekersky, D. N. Buell, M. Roden, J. Barrett, and E. J. Anaissie. 2001. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob. Agents Chemother. 45:3487-3496.
43. White, M. H., K. A. Bowden, E. S. Sandler, M. L. Graham, G. A. Noskin, J. R. Wingard, M. Goldman, J. A. van Burik, A. McCabe, J. S. Lin, M. Gurwith, and C. B. Miller. 1998. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin. Infect. Dis. 27:296-302.
44. Younes, A., and M. E. Kadin. 2003. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J. Clin. Oncol. 21:3526-3534.